Patent intelligence · US
US 11826321
Cyclobenzaprine treatment for agitation, psychosis and cognitive decline in dementia and neurodegenerative conditions
Cyclobenzaprine treatment for agitation, psychosis and cognitive decline in dementia and neurodegenerative conditions
Patent details — US 11826321
- Jurisdiction
- US
- Status
- granted
- Grant date
- Nov 28, 2023
- Expiration
- Nov 23, 2043
- Applicant
- TONIX PHARMA LIMITED
- Claims
- 7
- CPC classes
- A61K, A61K31/135, A61K45/06, A61K9/0056
Quick answer
US 11826321 (Cyclobenzaprine treatment for agitation, psychosis and cognitive decline in dementia and neurodegenerative conditions) is held by TONIX PHARMA LIMITED. Status: granted. Granted Nov 28, 2023. Expires Nov 23, 2043 (17 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- TONIX PHARMA LIMITED
- Grant date
- Expiration
- Claims
- 7
- CPC classes
- A61K, A61K31/135, A61K45/06, A61K9/0056, A61K9/006, A61K9/145
More from TONIX PHARMA LIMITED
Related pharmaceutical patents in our USPTO index.
-
US 12383733
Iontophoresis-based patch type medicine absorption device
granted -
US 12365879
Synthetic chimeric poxviruses
granted -
US 12304901
Selective ligands for tau aggregates
granted -
US 12156897
Magnesium-containing oxytocin formulations and methods of use
granted -
US 12156864
Analogs of cyclobenzaprine and amitryptilene
granted -
US 12097183
Pharmaceutical composition for treating migraine
granted -
US 12090139
Formulations comprising triptan compounds
granted -
US 11998516
Methods and compositions for treating depression using cyclobenzaprine
granted
Frequently asked questions
What is US patent 11826321?
US 11826321 (Cyclobenzaprine treatment for agitation, psychosis and cognitive decline in dementia and neurodegenerative conditions) is held by TONIX PHARMA LIMITED. Status: granted. Granted Nov 28, 2023. Expires Nov 23, 2043 (17 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 11826321?
TONIX PHARMA LIMITED is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 86 pharmaceutical patents for this assignee.
When does US 11826321 expire?
Our index shows an expiration date of Nov 23, 2043 (17 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.